KPC Pharmaceuticals

KPC Pharmaceuticals R&D per Employee

The R&D Spending per Employee of KPC Pharmaceuticals (600422.SS) as of Nov 4, 2026 is 19,268.73 CNY. In the previous year, R&D Spending per Employee was 20,060.38 CNY — a change of -3.95% (lower).

R&D per Employee

19,268.73CNY

YoY

-3.95%

Last updated:

R&D Spending per Employee of KPC Pharmaceuticals is 2025 19,268.73 CNY. R&D Spending per Employee of KPC Pharmaceuticals was 2024 20,060.38 CNY. It decreases by -3.95% lower compared to the previous year.

The KPC Pharmaceuticals R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
15,547.49 CNY
Jan 1, 2019
15,691.90 CNY
Jan 1, 2020
24,135.42 CNY
Jan 1, 2021
18,887.13 CNY
Jan 1, 2022
13,087.46 CNY
Jan 1, 2023
17,700.21 CNY
Jan 1, 2024
20,060.38 CNY
Jan 1, 2025
19,268.73 CNY
The KPC Pharmaceuticals R&D per Employee history
YEARR&D per EmployeeYoY
19,268.73CNY-3.95%
20,060.38CNY+13.33%
17,700.21CNY+35.25%
13,087.46CNY-30.71%
18,887.13CNY-21.75%
24,135.42CNY+53.81%
15,691.90CNY+0.93%
15,547.49CNY-29.41%
22,026.02CNY+18.17%
18,638.79CNY+25.64%
14,835.30CNY+364.48%
3,193.95CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KPC Pharmaceuticals Stock analysis

What does KPC Pharmaceuticals do? KPC Pharmaceuticals, Inc. generates revenue through the research, development, manufacturing, and international marketing of its diverse drug portfolio. The company sells natural herbal medicines, traditional Chinese medicines, and chemical synthetic drugs, including central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines, and anti-inflammatory drugs. Its main customers are healthcare providers, hospitals, and pharmaceutical distributors globally. The firm also produces health products and offers medical services as additional revenue streams. The company's product segments are defined by therapeutic categories such as central nervous system treatments, cardiovascular care, and anti-inflammatory solutions. These products target both domestic and international markets, with a focus on traditional Chinese medicine and natural herbal formulations. Sales are driven by wholesale distribution networks and direct commercial partnerships in the pharmaceutical industry. KPC Pharmaceuticals' revenue model combines product sales from its core drug lines with supplementary health product offerings and medical service provision. The business leverages its manufacturing capabilities in Kunming, Yunnan to serve global markets, with a strong emphasis on traditional Chinese medicine and natural herbal medicine segments. The firm's international marketing efforts support its presence in multiple regions. KPC Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KPC Pharmaceuticals stock

R&D Spending per Employee of KPC Pharmaceuticals is 19,268.73 CNY in 2025.

R&D Spending per Employee of KPC Pharmaceuticals changed from 20,060.38 CNY to 19,268.73 CNY, representing a -3.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee KPC Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's KPC Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — KPC Pharmaceuticals

All Key Metrics — KPC Pharmaceuticals